Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.
The present invention relates to a composition comprising an elecampane extract for prevention and alleviation or treatment of premenstrual syndrome. In detail, the composition can be advantageously available as a composition for preventing, and alleviating or treating premenstrual syndrome in women, which effectively suppresses pituitary prolactin secretion, which is a phenomenon appearing in premenstrual syndrome, to increase the progesterone release amount lowered in the luteal phase of women as well as effectively controlling the decreased release of luteinizing hormone and follicle-stimulating hormone.
The present invention relates to a composition for preventing and alleviating or treating glaucoma and macular degeneration, containing a Centella asiatica extract. Particularly, the composition increases the glucose metabolism efficiency of cells so as to increase the survival rate of retinal neurons and pigment epithelial cells and protects cells from oxidative damage caused by A2E, thereby being effectively usable as a composition for eye health and for preventing and alleviating or treating glaucoma and macular degeneration.
The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a chrysanthemum sibiricum extract; (b) a mixture of the chrysanthemum sibiricum extract and a malt extract; or (c) a mixture of the chrysanthemum sibiricum extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.
The present invention relates to a composition comprising an elecampane extract for prevention and alleviation or treatment of premenstrual syndrome. In detail, the composition can be advantageously available as a composition for preventing, and alleviating or treating premenstrual syndrome in women, which effectively suppresses pituitary prolactin secretion, which is a phenomenon appearing in premenstrual syndrome, to increase the progesterone release amount lowered in the luteal phase of women as well as effectively controlling the decreased release of luteinizing hormone and follicle-stimulating hormone.
The present invention relates to a composition for preventing and alleviating or treating glaucoma and mascular degeneration, containing a Centella asiatica extract. Particularly, the composition increases the glucose metabolism efficiency of cells so as to increase the survival rate of retinal neurons and pigment epithelial cells and protects cells from oxidative damage caused by A2E, thereby being effectively usable as a composition for eye health and for preventing and alleviating or treating glaucoma and mascular degeneration.
CULTURE MEDIUM COMPOSITION FOR CULTURING OF ANTI-CANCER ACTIVATED LYMPHOCYTES DERIVED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS AND METHOD FOR CULTURING ANTI-CANCER ACTIVATED LYMPHOCYTES USING SAME
The present invention relates to a culture medium composition for culturing anti-cancer activated lymphocytes derived from peripheral blood mononuclear cells and a method for culturing anti-cancer activated lymphocytes using same. More specifically, when the composition contains normal hexane fraction of Melia azedarach L., interleukin-2 (IL-2), anti-CD3 monoclonal antibody, and anti-CD16 monoclonal antibody, the effects of promoted differentiation and of mass proliferation of NK cells, NKT cells, and T cells (corresponding to anti-cancer activated lymphocytes) from peripheral blood mononuclear cells were confirmed. Accordingly, the present invention relates to a culture composition based on normal hexane fraction of Melia azedarach L. and a method for culturing peripheral blood mononuclear cells using same. Also, the anti-cancer activated lymphocytes derived from peripheral blood mononuclear cells cultured by the method according to the present invention can be used as a pharmaceutical composition which is highly effective for cancer treatment. Furthermore, the culture medium composition of the present invention may itself be used as an anti-cancer treatment, and when a chemical anticancer drug is administered in combination in a clinical use, the dosage of an existing anti-cancer drug can be lowered, thereby relieving side effects and greatly enhancing anticancer activity.
The present invention relates to a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus (HCV) infection. The pharmaceutical composition for preventing or treating diseases caused by HCV infection, according to the present invention, contains an Agrimonia sp. plant extract and a Rhus chinensis extract so as to be harmless to the human body and has an effect of effectively inhibiting HCV proliferation.
A61K 36/73 - Rosaceae (famille de la rose), p. ex. fraise, aronia, mûre ou pyracantha
A61K 36/22 - Anacardiaceae (famille du sumac), p. ex. cotinus, sumac ou sumac vénéneux
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
brevets
